Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This phase Ib study found that combining pegylated liposomal doxorubicin and pembrolizumab was well-tolerated and effective, with durable antitumor responses and a median survival of over two years in heavily pretreated ER-positive metastatic breast cancer patients.

This study found that treatment with ritlecitinib or brepocitinib was effective in improving scalp hair loss for patients with alopecia areata over 24 weeks compared to placebo.

In this review, the authors highlight the FDA approval of Ritlecitinib, the first oral treatment specifically for moderate to severe alopecia areata in patients aged 12 and older, marking a significant advancement in managing this condition.

This study reports a case of complete hair regrowth in lichen planopilaris after 12 weeks of treatment with ixekizumab, suggesting its potential as a targeted therapy.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

In this study, ritlecitinib was generally well tolerated in pediatric alopecia areata patients aged 6 to <12 years, with no severe or serious adverse events reported, and the drug's pharmacokinetic parameters were successfully characterized.

In this pilot study, Doxil at 60 mg/m² every 4 weeks showed activity against hormone-refractory prostate cancer but was limited by severe mucocutaneous toxicities.

This review discusses recent adult studies on systemic lupus erythematosus treatments and explores their implications for pediatric cases, emphasizing a critical need for more pediatric-focused research.

This research reported that the FDA approved Litfulo® (ritlecitinib) as the first oral treatment for severe alopecia areata in adolescents over 12 years old, with 23% of treated patients showing significant hair regrowth in clinical trials compared to 1.6% with placebo.

This study reported that ritlecitinib was prescribed to a diverse group of patients with severe alopecia areata in the first 10 months after FDA approval, indicating its potential role in AA management.

This study found that combining intralesional PTX and corticosteroids may enhance treatment outcomes for alopecia areata, with PTX showing better long-term effects compared to corticosteroids alone.

This study found that ruxolitinib modulated inflammatory changes and stimulated growth factor signals by blocking the JAK-STAT pathway in an in vitro model of alopecia areata.

This review discusses current treatments for discoid lupus erythematosus and highlights anifrolumab as a promising option for difficult cases, but no new clinical results are reported.

This review highlights PRF's potential as a regenerative medicine tool, detailing its diverse applications in dentistry, orthopedics, and dermatology, but presents no new clinical results.

This study found that among adolescents with alopecia areata and significant hair loss, treatment with ritlecitinib resulted in greater hair regrowth and self-reported improvement compared to placebo over 48 weeks, with common side effects including headache, acne, and nasopharyngitis.

This systematic review assessed the off-label use of topical Ruxolitinib cream for various skin conditions and found it effective for lichenoid and granulomatous dermatoses, though results for alopecia areata were inconsistent. The authors indicate that further research is warranted to confirm these findings.

In a post-hoc analysis of six trials, this study observed that both adult and pediatric patients with moderate-to-severe palmoplantar psoriasis treated with ixekizumab experienced rapid and complete clearance of lesions, sustained for up to 5 years in adults and 2 years in children.

This study compared JAK inhibitors for moderate-to-severe alopecia areata and found brepocitinib 30mg and deuruxolitinib 12mg to be most effective, though deuruxolitinib may cause more adverse events. Further research is needed for long-term efficacy and safety.

This source reports that JAK inhibitors, such as ruxolitinib, baricitinib, and tofacitinib, have led to hair regrowth in alopecia areata patients and animal models, but their long-term safety and effectiveness remain uncertain, with ongoing trials to further investigate these factors.

In this study using a mouse model with alopecia areata, the researchers found that ruxolitinib enhances hair regrowth by inhibiting the JAK-STAT signaling pathway, reducing inflammation and oxidative stress, and decreasing apoptosis, which supports its clinical effectiveness in treating this condition.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

This article reviews adverse drug reactions, emphasizes methods of prevention, and encourages reporting to the FDA's medWatch program, but presents no new study findings.

This research discusses the parallel clinical development of ritlecitinib, an oral Janus kinase 3/tyrosine kinase inhibitor, for treating conditions such as alopecia areata, vitiligo, ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Results are not reported in the abstract.

This study highlights that topical ruxolitinib cream is FDA-approved for mild to moderate atopic dermatitis and nonsegmental vitiligo in patients aged 12 and older, but its use in other skin conditions like frontal fibrosing alopecia remains under-researched and needs further exploration in clinical practice.

This study found that topical ruxolitinib protected Lgr5+ skin stem cells and maintained skin homeostasis in skin GVHD, unlike corticosteroids.

In this study, a single subcutaneous dose of PTH-CBD showed similar hair regrowth to daily oral ruxolitinib in mice with alopecia, possibly through increased beta-catenin and anagen transition stimulation.

This study found that JAK inhibitors used to treat alopecia areata have varied safety profiles, with different adverse events associated with each drug; tofacitinib and ruxolitinib had earlier onset of events, while baricitinib and ritlecitinib showed distinct delayed patterns.

PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.

This case study reports a successful use of co-trimoxazole in treating a 13-year-old girl with symptoms suggestive of autoimmune disorders and relapsing polychondritis.